The United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) at Aurobindo Pharma’s stepdown subsidiary -- Eugia Steriles’ manufacturing facility, situated at Parawada Mandal, Anakapalli District, Andhra Pradesh, from June 10, 2026, to June 19, 2026. The inspection concluded with 5 observations and will be responded to within the stipulated time.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
